[Federal Register Volume 60, Number 167 (Tuesday, August 29, 1995)]
[Notices]
[Page 44860]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-21323]



-----------------------------------------------------------------------


DEPARTMENT OF DEFENSE

Availability of Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning Protective Peptides of 
Neurotoxin of C. Botulinum

AGENCY: U.S. Army Medical Research and Material Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability of U.S. Patent Application SN 08/446,114, entitled 
``Protective Peptides of Neurotoxin of C. Botulinum,'' and filed May 
19, 1995, for licensing. This patent has been assigned to the United 
States Government as Represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, Fort Detrick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, 301-619-2065 or telefax 301-619-
7714.

SUPPLEMENTARY INFORMATION: A plasmid-based expression vector has been 
constructed for genetic fusion of antigenic peptides to cholera toxin, 
which is predicted to eliminate many of the problems associated with 
direct conjugation of large proteins to the B subunit of this protein. 
Cholera toxin fusion proteins can be used to improve the immunogenicity 
of any vaccine and allow immunization by any number of different 
routes. These fusion proteins may also aid in the treatment of 
autoimmune disorders by inducing oral tolerance to the target antigen 
conjugated to cholera toxin. The described methods allows bacterial 
expression of fusion protein in sufficient quantities for vaccine and 
diagnostic use.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 95-21323 Filed 8-28-95; 8:45 am]
BILLING CODE 3710-08-M